Isabel Britsch

6PUBLICATIONS
9CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 29, 2025
CD19-ReTARGTPR: A Novel Fusion Protein for Physiological Engagement of Anti-CMV Cytotoxic T Cells Against CD19-Expressing Malignancies.

Anne Paulien van Wijngaarden, Isabel Britsch, Matthias Peipp

|Sep 21, 2023
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.

Emily Maria Ploeg, Douwe Freerk Samplonius, Xiao Xiong

|Aug 12, 2023
Applications of Anti-Cytomegalovirus T Cells for Cancer (Immuno)Therapy.

Isabel Britsch, Anne Paulien van Wijngaarden, Wijnand Helfrich

|May 14, 2023
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells.

Isabel Britsch, Anne P van Wijngaarden, Xiurong Ke

|Dec 03, 2021
Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis.

Mark A J M Hendriks, Isabel Britsch, Xiurong Ke

|Dec 10, 2020
Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.

Mark A J M Hendriks, Emily M Ploeg, Iris Koopmans

Pageof 1

Frequent Collaborators

6 joint publications

Wijnand Helfrich

5 joint publications

Douwe Freerk Samplonius

5 joint publications

Anne Paulien van Wijngaarden

4 joint publications

Mark Alexander Johannes Martinus Hendriks